Balyasny Asset Management
CTMX icon

Balyasny Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Balyasny Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.43M Sell
730,844
-3,141,358
-81% -$15.9M ﹤0.01% 1535
2025
Q4 		$16.5M Sell
3,872,202
-40,879
-1% -$155K 0.02% 811
2025
Q3 		$12.5M Buy
3,913,081
+1,047,456
+37% +$2.36M 0.02% 943
2025
Q2 		$6.5M Buy
+2,865,625
New +$4.62M 0.01% 1167
2024
Q2 		– Sell
-31,921
Closed -$69.6K – 2652
2024
Q1 		$69.6K Buy
+31,921
New +$58.9K ﹤0.01% 2510
2023
Q1 		– Sell
-34,800
Closed -$55.7K – 2734
2022
Q4 		$55.7K Buy
34,800
+20,006
+135% +$29.6K ﹤0.01% 2335
2022
Q3 		$21K Sell
14,794
-1,758
-11% -$2.71K ﹤0.01% 2578
2022
Q2 		$30K Buy
+16,552
New +$31.7K ﹤0.01% 2424
2021
Q3 		– Sell
-10,059
Closed -$64K – 2012
2021
Q2 		$64K Buy
+10,059
New +$78.3K ﹤0.01% 1836
2018
Q3 		– Sell
-16,632
Closed -$380K – 1722
2018
Q2 		$380K Buy
16,632
+1,157
+7% +$29.6K ﹤0.01% 1431
2018
Q1 		$440K Buy
+15,475
New +$442K ﹤0.01% 1484

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management's CTMX Position: Q1 2026 in Review

Balyasny Asset Management reduced its CytomX Therapeutics (CTMX) stake by 81% in Q1 2026, selling an estimated $15.9M and leaving 730,844 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

Balyasny Asset Management first reported a position in CTMX in Q1 2018 and has held it in 11 quarters since. The position peaked at $16.5M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Balyasny Asset Management held 730,844 shares of CytomX Therapeutics worth $3.43M as of Q1 2026.
  • Balyasny Asset Management sold 3,141,358 CytomX Therapeutics shares in Q1 2026, an estimated $15.9M.
  • CytomX Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1535 holding.
  • Balyasny Asset Management first reported a position in CytomX Therapeutics in Q1 2018 and has held it in 11 quarters since.
  • Balyasny Asset Management's CytomX Therapeutics position peaked at $16.5M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.